Cart
sales@molnova.com
Infliximab
CAS No. 170277-31-3
Infliximab( —— )
Catalog No. M22152 CAS No. 170277-31-3
Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 146 | In Stock |
|
| 5MG | 246 | In Stock |
|
| 10MG | 357 | In Stock |
|
| 25MG | 597 | In Stock |
|
| 50MG | 851 | In Stock |
|
| 100MG | 1152 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameInfliximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionInfliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.
-
DescriptionInfliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number170277-31-3
-
Formula Weight149 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dahlén R, et al. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis.Scand J Immunol. 2013 Sep;78(3):275-84.
molnova catalog
related products
-
GSK963 (Racemate)
GSK963 (Racemate) a structurally distinct potent and selective inhibitor of RIP1 kinase(IC50=29?nM).
-
Brentuximab
Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.
-
Armepavine
Armepavine exerted both in vitro and in vivo antifibrotic effects in rats, with inhibition of NF-κB, JunD and C/EBP? pathways.
